SEC Comment Letter 0000000000-24-012346 to Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc.
Date: Nov. 6, 2024 · CIK: 0001517681 · Accession: 0000000000-24-012346
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282886
Letter
November 6, 2024 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Australia Re:Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed October 30, 2024 File No. 333-282886 Dear James Nathanielsz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Chase Chandler, Esq.
Show Raw Text
November 6, 2024
James Nathanielsz
Chief Executive Officer
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC 3124 Australia
Re:Propanc Biopharma, Inc.
Registration Statement on Form S-1
Filed October 30, 2024
File No. 333-282886
Dear James Nathanielsz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Chase Chandler, Esq.